{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:58:57Z","timestamp":1780822737589,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR075777"],"award-info":[{"award-number":["R01AR075777"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","award":["NPF1808UC"],"award-info":[{"award-number":["NPF1808UC"]}],"id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ard.2025.10.014","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:58:30Z","timestamp":1762552710000},"page":"630-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inadequate response to anti-TNF\u03b1 therapy is associated with a gain-of-function TNFR2-R polymorphic variant in patients with psoriatic arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-1590","authenticated-orcid":false,"given":"James K.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Del","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Cheemalavagu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-9729","authenticated-orcid":false,"given":"Jean","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-246X","authenticated-orcid":false,"given":"Sujay S.","family":"Ithychanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0761-2590","authenticated-orcid":false,"given":"Unnikrishnan M.","family":"Chandrasekharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-4205","authenticated-orcid":false,"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ard.2025.10.014_bib0001","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"Silva","year":"2010","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.ard.2025.10.014_bib0002","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.ard.2025.10.014_bib0003","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.10.014_bib0005","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/kez427","article-title":"Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA","volume":"59","author":"Brahe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.10.014_bib0006","first-page":"191","article-title":"Pharmacogenomics: the right drug to the right person","volume":"1","author":"Aneesh","year":"2009","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.ard.2025.10.014_bib0007","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/978-1-0716-2573-6_19","article-title":"Pharmacogenetics of drug therapies in rheumatoid arthritis","volume":"2547","author":"Aluko","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10067-020-05258-2","article-title":"Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine","volume":"40","author":"Daniel","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.10.014_bib0009","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/FPC.0000000000000140","article-title":"Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study","volume":"25","author":"Canet","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.ard.2025.10.014_bib0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/apt.13736","article-title":"Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases","volume":"44","author":"Bek","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"31","key":"10.1016\/j.ard.2025.10.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011677","article-title":"Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis","volume":"97","author":"Xing-Rong","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.ard.2025.10.014_bib0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00403-014-1533-z","article-title":"The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients","volume":"307","author":"Gonz\u00e1lez-Lara","year":"2015","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.ard.2025.10.014_bib0013","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/jdv.15431","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Ovejero-Benito","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ard.2025.10.014_bib0014","unstructured":"TNFRSF1B: Chr1 - Genome Data Viewer - NCBI [Internet]. [cited 2022 Mar 11]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/genome\/gdv\/browser\/gene\/?id=7133"},{"issue":"12","key":"10.1016\/j.ard.2025.10.014_bib0015","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1097\/01.TP.0000092496.05951.D5","article-title":"Tumour necrosis factor receptor type II 196M\/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation","volume":"76","author":"Stark","year":"2003","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ard.2025.10.014_bib0016","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1210\/jcem.87.8.8715","article-title":"Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism","volume":"87","author":"Peral","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0017","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1034\/j.1399-0039.2000.550122.x","article-title":"Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus","volume":"55","author":"Al-Ansari","year":"2000","journal-title":"Tissue Antigens"},{"issue":"3","key":"10.1016\/j.ard.2025.10.014_bib0018","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"7","key":"10.1016\/j.ard.2025.10.014_bib0019","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/ket363","article-title":"Age at disease onset: a key factor for understanding psoriatic disease","volume":"53","author":"Queiro","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ard.2025.10.014_bib0020","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non\u2013TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ard.2025.10.014_bib0021","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2006-05-020875","article-title":"Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo","volume":"109","author":"Chandrasekharan","year":"2007","journal-title":"Blood"},{"issue":"284","key":"10.1016\/j.ard.2025.10.014_bib0022","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2003743","article-title":"Release of nonmuscle myosin II from the cytosolic domain of tumor necrosis factor receptor 2 is required for target gene expression","volume":"6","author":"Chandrasekharan","year":"2013","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.1993.tb00143.x","article-title":"Soluble intercellular adhesion molecule-1 levels in patients with psoriasis","volume":"128","author":"Schopf","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ard.2025.10.014_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1229516","article-title":"Cytokine profile characterization of na\u00efve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum","volume":"14","author":"Ruscitti","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ard.2025.10.014_bib0025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.ard.2025.10.014_bib0026","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nrm1128","article-title":"Rocks: multifunctional kinases in cell behaviour","volume":"4","author":"Riento","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.ard.2025.10.014_bib0027","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13075-016-0995-0","article-title":"Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study","volume":"18","author":"Han","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.ard.2025.10.014_bib0029","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.10.014_bib0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.30130","article-title":"Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci","volume":"63","author":"Plant","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.ard.2025.10.014_bib0031","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/annrheumdis-2012-202405","article-title":"Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis","volume":"72","author":"Umi\u010bevi\u010b Mirkov","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.10.014_bib0032","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/tpj.2015.31","article-title":"A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis","volume":"16","author":"Juli\u00e0","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.ard.2025.10.014_bib0033","series-title":"ALFA: allele frequency aggregator [Internet]","author":"Phan","year":"2025"},{"issue":"3, Pt 1","key":"10.1016\/j.ard.2025.10.014_bib0034","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/jid.2011.376","article-title":"TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis","volume":"132","author":"Tejasvi","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","article-title":"The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0036","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.intimp.2015.05.049","article-title":"The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: a meta-analysis","volume":"28","author":"Chen","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ard.2025.10.014_bib0037","series-title":"Medical genetics summaries [Internet]","article-title":"Allopurinol therapy and HLA-B*58:01 genotype","author":"Dean","year":"2012"},{"issue":"4","key":"10.1016\/j.ard.2025.10.014_bib0038","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40744-020-00226-3","article-title":"Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis","volume":"7","author":"Bergman","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.ard.2025.10.014_bib0039","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/GIM.0b013e318163c35f","article-title":"Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin","volume":"10","author":"Flockhart","year":"2008","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.ard.2025.10.014_bib0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrrheum.2011.117","article-title":"Pharmacogenetics: implications for therapy in rheumatic diseases","volume":"7","author":"Davila","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.10.014_bib0041","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants - past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/j.ard.2025.10.014_bib0042","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jdermsci.2014.11.008","article-title":"TNF inhibitors directly target Th17 cells via attenuation of autonomous TNF\/TNFR2 signalling in psoriasis","volume":"77","author":"Shiga","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.ard.2025.10.014_bib0043","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3389\/fimmu.2018.00583","article-title":"The significance of tumor necrosis factor receptor type II in CD8 + regulatory T cells and CD8 + effector T cells","volume":"9","author":"Ye","year":"2018","journal-title":"Front Immunol"},{"issue":"34","key":"10.1016\/j.ard.2025.10.014_bib0044","doi-asserted-by":"crossref","first-page":"17045","DOI":"10.1073\/pnas.1902091116","article-title":"TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes","volume":"116","author":"Fischer","year":"2019","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.ard.2025.10.014_bib0045","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.106.647255","article-title":"Tumor necrosis factor-\u03b1 receptor p75 is required in ischemia-induced neovascularization","volume":"115","author":"Goukassian","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ard.2025.10.014_bib0046","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/ATVBAHA.110.204222","article-title":"Endothelial-specific transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogenesis","volume":"30","author":"Luo","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ard.2025.10.014_bib0047","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bbi.2024.09.002","article-title":"TNFR2 signaling in oligodendrocyte precursor cells suppresses their immune-inflammatory function and detrimental microglia activation in CNS demyelinating disease","volume":"123","author":"Desu","year":"2025","journal-title":"Brain Behav Immun"},{"issue":"6","key":"10.1016\/j.ard.2025.10.014_bib0048","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/jcp.25219","article-title":"TNF-\u03b1\/TNFR2 regulatory axis stimulates EphB2-mediated neuroregeneration via activation of NF-\u03baB","volume":"231","author":"Pozniak","year":"2016","journal-title":"J Cell Physiol"},{"issue":"10","key":"10.1016\/j.ard.2025.10.014_bib0049","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/s42255-020-00271-w","article-title":"Stable human regulatory T cells switch to glycolysis following TNF receptor 2 costimulation","volume":"2","author":"de Kivit","year":"2020","journal-title":"Nat Metab"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672504453X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672504453X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:19:32Z","timestamp":1780820372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672504453X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S000349672504453X"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.014","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inadequate response to anti-TNF\u03b1 therapy is associated with a gain-of-function TNFR2-R polymorphic variant in patients with psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}